Avalo Therapeutics

Ashley Ivanowicz is an HR executive with nearly 20 years of biotech and pharmaceutical experience. She previously led HR at Venatorx Pharmaceuticals and held leadership roles at Aralez, Endo, and Auxilium.

Chris Sullivan has been Avalo's CFO since February 2022, having previously served as its Chief Accounting Officer and Interim CFO. He was earlier Corporate Controller at Sucampo Pharmaceuticals and OpGen and a Senior Manager at Ernst & Young.

Colleen Matkowski brings over 25 years of biopharmaceutical regulatory experience to Avalo. She previously was Head of Regulatory Affairs at Aclaris Therapeutics and held regulatory roles at Takeda, BioMarin, and other firms, beginning her career at the FDA.

Dino Miano has more than 25 years of pharmaceutical development experience in analytical and product development and manufacturing. He previously served as an Executive Director at Alexion Pharmaceuticals supporting commercialization of several rare-disease therapies.

Garry Neil has served as CEO of Avalo Therapeutics since February 2022, previously acting as its Chief Scientific Officer following the 2020 merger with Aevi Genomic Medicine. He has held senior pharmaceutical roles at Johnson & Johnson, Merck KGaA, and AstraZeneca, and serves on the board of Celldex Therapeutics.

Gilla Kaplan is an authority on host immune response to mycobacterial pathogens and formerly directed the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation. She served on Celgene's board and is currently a board member at Tyra Biosciences.

Jennifer Riley has over 20 years of biotech and pharmaceutical leadership experience as Avalo's Chief Strategy Officer. She founded Northbrook Consulting and previously held senior roles at Biogen, including VP of Program Leadership and Management.

Kathleen Cohen brings over 25 years of clinical research and development experience to her role leading Clinical Development Operations at Avalo. She previously spent over two decades at a global CRO and holds a PharmD from the University of the Sciences in Philadelphia.

Kevin Lind is a biotechnology executive with more than 20 years of leadership experience who led Longboard Pharmaceuticals through its $2.6 billion acquisition by Lundbeck. He was previously EVP and CFO at Arena Pharmaceuticals and chairs the board of Apnimed.

Michael Heffernan is a biopharmaceutical executive with over 30 years of experience and founder of Collegium Pharmaceutical. He chairs the boards of NMD Pharma and Aavantgarde Bio and sits on boards of Biohaven, Trevi Therapeutics, and K36 Therapeutics.

Mittie Doyle is a research physician with over 20 years of pharmaceutical/biotech experience who serves as Avalo's Chief Medical Officer. She previously held the CMO role at Aro Biotherapeutics and senior positions at CSL Behring, Shire, Flexion, and Alexion.

Paul Varki brings 25 years of legal experience in the pharmaceutical and biotech industry as Avalo's Chief Legal Officer. He previously served as US General Counsel at Idorsia and held legal leadership roles at Amarin, Braeburn, Egalet, and GSK.

Rita Jain is a rheumatologist with over two decades of biopharmaceutical development and regulatory leadership experience. She most recently was CMO at ChemoCentryx and previously held roles at Akebia, AbbVie, Pfizer, and Immunovant.

Ron Philip is Executive Chair of CREATE Medicines and previously CEO of Orbital Therapeutics before its acquisition by Bristol Myers Squibb. He held leadership roles at Spark Therapeutics, including CEO, where he led the launch of LUXTURNA.

Taylor Boyd has nearly 15 years of experience in biotech business development, corporate finance, and investment banking. He previously served as Chief Business Officer at Abzena and Head of Business Development at Longboard Pharmaceuticals.

Samantha Truex is CEO of Oblenio Bio and CEO-in-Residence at Aditum Bio, and serves on the boards of Avalo and Artios Pharma. She was founding CEO of Upstream Bio and previously held corporate development leadership roles at Biogen and Genzyme.